Novo-Profen · DIN 00629359 · 600 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-23 — choose a marketed DIN from the same-category list.Discontinued July 23, 2025 · checked November 19, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-23 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-07-23 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Novo-Profen · DIN 00629359
Manufacturer: Novopharm Ltd.; listing date 1996-10-01
Health Canada: Cancelled post market since 2025-07-23 · brand TEVA-PROFEN · ATC M01AE01 IBUPROFEN · form Tablet · route Oral · ingredients IBUPROFEN 600 MG · company Teva canada limited · schedule Prescription
Novo-Profen: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1313). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00629359)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00629359).
DIN 00629359: Novo-Profen
Raw flags: dinStatus=E, sec3=Y
Item: 280804022; group id 382; item number 0914; lccId None; manufacturer id NOP
Source form: Tab; strength: 600mg
Recorded listing: General benefit; DIN status E, meaning unconfirmed
Source prices (unrounded): $0.1313; ministry $0.1313
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00629359
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6323
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ibuprofen · DIN 00585114 · $0.1313
Motrin · DIN 00484911 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since July 23, 2025 — choose a marketed DIN from the same-category list.